title: Once-daily therapy: less is more.
abstract: Over the last 20 years, a trend towards regimens with less frequent dosing has been observed across medicine. Recent surveys of people with HIV indicate that there is a strong preference for once-daily dosing and compact therapy. Four antiretrovirals (tenofovir, didanosine, lamivudine and efavirenz) are now available as once-a-day therapies. The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12-18 months.
authors: HIV Research Department, Chelsea and Westminster Hospital, London, UK. gm@moyleg.demon.co.uk
authors: G
authors: G
authors: Moyle
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004334:Drug Administration Schedule; D005060:Europe; D015658:HIV Infections / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D010349:Patient Compliance; D014481:United States
chemical_list: D019380:Anti-HIV Agents